The agreement for exclusive rights to potential specialty blockbuster product in the US completed

The agreement for exclusive rights to potential specialty blockbuster product in
the US completed

On September 5th, Meda announced the exclusive license agreement with
BioDelivery Sciences International Inc (BDSI) for marketing of a potential
specialty blockbuster product in the US, Canada and Mexico. The product, BEMA
Fentanyl, is patented with a unique delivery system designed to give rapid and
reliable delivery of fentanyl for treatment of breakthrough pain in cancer
patients. BEMA Fentanyl has shown in clinical studies important patient
advantages compared to competing products, especially fewer side effects.

The agreement with BDSI was to become effective upon antitrust approval by the
Federal Trade Commission (FTC). Meda has been informed by the FTC that this
review will not be undertaken. The agreement with BDSI has therefore been
completed and the collaboration starts with immediate effect. Filing for
registration of BEMA Fentanyl with the FDA (Food and Drug Administration) is
planned this year, giving a potential launch in late 2008. 


For more information, please contact:

Anders Larnholt, Investor Relations, tel. +46 709 458 878

Meda AB  
MEDA AB (publ) is an international specialty pharma company that concentrates on
marketing and market-adapted product development. Acquisitions and long-term
partnerships are fundamental factors that drive the company's strategy. Meda is
represented with own organisations in 26 countries and with more than 1 500
employees within marketing and sales. Meda's products are sold in approximately
120 countries world-wide. The Meda share is listed under Large Cap on the OMX
Nordic Stock Exchange. Find out more, visit www.meda.se.